Literature DB >> 11563589

Risk factors for early death in patients undergoing treatment for multiple myeloma.

H Murakami1, K Hayashi, N Hatsumi, T Saitoh, A Yokohama, T Matsushima, N Tsukamoto, K Morita, M Karasawa, H Ogawara, M Sawamura, Y Nojima.   

Abstract

The survival time of myeloma patients improved from a few months to many years after treatment with melphalan. Perhaps chemotherapy more intensive than melphalan-prednisolone should be administered to patients at risk of early death. Therefore, early death must be accurately predicted. We analyzed 93 patients with recently diagnosed myeloma and found that 13 (14%) died within 6 months (early death). The most common cause of death was bacterial and fungal pneumonia when myeloma became uncontrollable. The response to conventional chemotherapy was poorer in patients at high risk of early death than the control group. Multivariate analysis showed that the serum level of beta-2 microglobulin was the only value that predicted early death.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11563589     DOI: 10.1007/s002770100330

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  6 in total

1.  Common community-acquired infections and subsequent risk of multiple myeloma: a population-based study.

Authors:  Charlene M McShane; Liam J Murray; Eric A Engels; Ola Landgren; Lesley A Anderson
Journal:  Int J Cancer       Date:  2013-10-12       Impact factor: 7.396

2.  Recognition of early mortality in multiple myeloma by a prediction matrix.

Authors:  Howard Terebelo; Shankar Srinivasan; Mohit Narang; Rafat Abonour; Cristina Gasparetto; Kathleen Toomey; James W Hardin; Gail Larkins; Amani Kitali; Robert M Rifkin; Jatin J Shah
Journal:  Am J Hematol       Date:  2017-07-19       Impact factor: 10.047

3.  Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma.

Authors:  Chun-Teng Huang; Chia-Jen Liu; Po-Shen Ko; Han-Tsung Liu; Yuan-Bin Yu; Liang-Tsai Hsiao; Jyh-Pyng Gau; Cheng-Hwai Tzeng; Tzeon-Jye Chiou; Jin-Hwang Liu; Muh-Hwa Yang; Ling-Ju Huang; Chun-Yu Liu
Journal:  BMC Infect Dis       Date:  2017-01-06       Impact factor: 3.090

4.  Development of a Risk Assessment Model for Early Grade ≥ 3 Infection During the First 3 Months in Patients Newly Diagnosed With Multiple Myeloma Based on a Multicenter, Real-World Analysis in China.

Authors:  Yufeng Shang; Weida Wang; Yuxing Liang; Natasha Mupeta Kaweme; Qian Wang; Minghui Liu; Xiaoqin Chen; Zhongjun Xia; Fuling Zhou
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

5.  Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).

Authors:  Zoe McQuilten; Cameron Wellard; Elizabeth Moore; Bradley Augustson; Krystal Bergin; Hilary Blacklock; Simon Harrison; P Joy Ho; Tracy King; Hang Quach; Peter Mollee; Brian Rosengarten; Patricia Walker; Erica Wood; Andrew Spencer
Journal:  Br J Haematol       Date:  2022-07-11       Impact factor: 8.615

6.  Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma.

Authors:  Pei Hsu; Ting-Wei Lin; Jyh-Pyng Gau; Yuan-Bin Yu; Liang-Tsai Hsiao; Cheng-Hwai Tzeng; Po-Min Chen; Tzeon-Jye Chiou; Jin-Hwang Liu; Yao-Chung Liu; Chia-Jen Liu
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.